Preventing the evolution of transmissible nitroimidazole resistance in Mycobacterium tuberculosis

防止结核分枝杆菌传染性硝基咪唑耐药性的演变

• 批准号: nhmrc : GNT1139832
• 负责人: A/Pr Colin Jackson
• 金额: $ 66.45万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/preventing-evolution-transmissible-mycobacterium-tuberculosis/1348260
• 关键词: Preventing; evolution; transmissible; nitroimidazole; resistance

Tuberculosis kills more people than any other infectious disease. Unfortunately, the drugs available to us to treat TB are losing their efficacy due to the evolution of drug resistance. A new class of drugs, nitroimidazoles, has been developed, but there is a risk that the bacterium that causes TB will develop resistance to these compounds too. We will identify resistance mutations before they occur in the wild, to help identify them and find new compounds for which resistance cannot develop.

肺结核比其他任何传染病都要多。不幸的是，由于耐药性的演变，我们可用于治疗结核病的药物正在失去效力。已经开发出了一类新的药物，硝基咪唑类，但导致结核病的细菌也有可能对这些化合物产生耐药性。我们将在耐药突变在野外发生之前识别它们，以帮助识别它们并找到不会产生耐药性的新化合物。